Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
3 hedge funds and large institutions have $8.12K invested in Reviva Pharmaceuticals Warrants in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0.33% less ownership
Funds ownership: 0.53% → 0.2% (-0.33%)
25% less funds holding
Funds holding: 4 → 3 (-1)
79% less capital invested
Capital invested by funds: $38.6K → $8.12K (-$30.4K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$644 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Walleye Capital
New York
| $4.55K | – | – | – |
|
2
Walleye Trading
New York
| $3.47K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $90 | -$644 | -3,995 | -86% |
|
RVPHW Hedge Fund Activity: Q3 2024 in Review
3 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q3 2024, worth a combined $8.12K — down 79% from $38.6K a quarter earlier.
Fund positioning in RVPHW was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $644.
- 3 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q3 2024, down from 4 in Q2 2024.
- Funds reported $8.12K of Reviva Pharmaceuticals Warrants stock for Q3 2024, down 79% quarter-over-quarter.
- 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q3 2024 and 0 closed out.
- The largest Reviva Pharmaceuticals Warrants seller in Q3 2024 was UBS Group, an estimated $644 sold.
Based on aggregated 13F filings for Q3 2024.